GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2012

Poll on ‘Strategy for UK Life Sciences’ Shows Divide

  • The jury seems to be out on how effective the U.K.’s new strategy for enhancing its competitiveness in biopharma will be, if a recent GEN poll is any evidence. More than one-third of respondents (35.6%) said they didn't think the plan would do very much, though more than half gave the strategy better marks by predicting it would be “a great deal” effective (25.4%) or “somewhat” effective (28.8%). The remaining 10.2% of respondents were undecided.

    Prime Minister David Cameron recently unveiled “Strategy for UK Life Sciences” with the intent of shepherding more biopharma companies to market and keeping them growing. The strategy calls for the U.K. to launch a £180 million ($278.6 million) fund to push startup companies past the “valley of death,” a £130 million ($201.2 million) personalized medicine research fund, and a £50 million ($77.4 million) cell therapy technology center among other components. The strategy also promises a new initiative to speed up approvals of new drugs.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?